Skip to main content
Article

Difficult-to-treat rheumatoid arthritis. What is it?

А. В. ГордеевYu. A. OlyuninV.A. Nasonova Research Institute of RheumatologyЕ. А. ГалушкоE. G. ZotkinА. М. ЛилаV.A. Nasonova Research Institute of Rheumatology; 34A, Kashirskoe Shosse, Moscow 115522, Russia; 22/1
2021en
ABI

Abstract

The widespread introduction into clinical practice of modern approaches to the treatment of rheumatoid arthritis (RA), the rational use of traditional and targeted antirheumatic drugs can effectively suppress inflammatory activity, restrain the progression of the disease and improve the quality of life of patients. At the same time, in some patients, even after the repeated change of targeted drugs, it is not possible to achieve the target level of RA activity. Serious difficulties arising in the management of such patients raised the question of identifying a special variant of the disease – difficult-to-treat (D2T) RA. The presence of various variants of D2T RA and the need to use a personalized approach to therapy justify the creation of special recommendations for the management of this category of patients. The first step in preparing these recommendations was the definition of D2T RA recently presented by the EULAR working group. It includes three criteria: 1) insufficient effectiveness of the therapy; 2) the presence of an active symptomatic disease; 3) clinical perception.

Identifiers

Citations and references

Cited by 20 references